跳到主要內容

臺灣博碩士論文加值系統

(18.206.76.226) 您好!臺灣時間:2021/07/30 22:25
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:鄭丞傑
研究生(外文):Cherng-Jye Jeng
論文名稱:直接向消費者行銷之處方藥的行銷策略:以威而鋼為例
論文名稱(外文):The Marketing Strategy of DTC (Direct-to-Consumer) Prescription Drug: Viagra as an Example
指導教授:黃恆獎黃恆獎引用關係
指導教授(外文):Heng-Chiang Huang
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:高階公共管理組
學門:社會及行為科學學門
學類:公共行政學類
論文種類:學術論文
論文出版年:2008
畢業學年度:97
語文別:中文
論文頁數:110
中文關鍵詞:直接向消費者行銷處方藥勃起功能障礙消費者行為行銷策略
外文關鍵詞:Direct-to-Consumer (DTC)Prescription DrugErectile Dysfunction(ED)Consumer BehaviorMarketing Strategy.
相關次數:
  • 被引用被引用:4
  • 點閱點閱:2184
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
直接向消費者行銷(DTC)處方藥名義上是醫師處方藥,但實際上卻和一般消費性商品比較接近,在行銷管理策略方面,也和一般消費性商品相似。
依照政府的法令規定,處方藥除了針對醫師之外,不得做任何形式的廣告促銷,然而消費者行為的研究卻顯示勃起功能障礙藥物(一種自費型藥品,也是DTC處方藥),消費者九成是未經醫師處方即直接向藥局購買,或者第一次看過醫師之後,即改為直接在藥局購買。研究也顯示,醫師或藥師對DTC處方藥的消費者影響不大,反而是大眾媒體和朋友之間的口耳相傳影響最大,這和一般的醫師處方藥不同,反倒是和一般消費性商品相似。
由於是處方藥,因此DTC處方藥的行銷仍需先取得醫學界的認同。然而行銷的主要對象,應該針對末端的消費者,並且是以記者會、廣編稿(一種看起來似新聞報導的廣告)、節慶活動等形式出現的「拉」的策略,另外再佐以不時地產品正面形象或效益宣導之「推」的策略。
DTC處方藥之消費起初可能是高涉入流程,以勃起功能障礙藥物為例,廠商皆為世界級藥廠,技術層次和藥效上的差異並不顯著,因此品牌差異不大,會轉變為低涉入之習慣性購買行為,如能一開始即建立消費者之品牌熟悉度,即易使其學習到品牌信念,而長期習慣購買同一品牌之產品。
DTC處方藥之促銷,固然以末端消費者之「拉」的策略,容易喚起潛在消費者之需求與消費者動機,進而透過行為學習流程或享樂過程強化其對產品的態度;然而也正因其「消費性商品」之本質,潛在消費者之消費意願會使得行銷效果大打折扣,擴大整體市場的努力容易受到侷限。
在成本優勢不容易突破的狀況下,DTC處方藥的市場領導者可以仰賴先驅者優勢和供給面的差異化,例如產品的特色與效能、行銷活動的密度…等,去維持長期的優勢。
由於DTC處方藥有專利期限,當產品生命週期即將進入成熟或衰退期的時候,企業應該及早因應,思考推出相對低價的相似產品繼續維持未來的市場優勢,或者退出市場,把重心轉向其他領域。

關鍵字:直接向消費者行銷、處方藥、勃起功能障礙、消費者行為、行銷策略
Although DTC(direct-to-consumer) prescription drugs are limited to be prescribed by medical doctors, it’s analogous to consumer products in certain aspects and its marketing strategy is similar to that of consumer goods.
According to the regulatory rules in Taiwan, prescription drugs can not use any form of advertisement except for promotion to medical doctors. However consumer behavior research revealed that more than 90% of erectile dysfunction(ED) drugs were directly sold in drugstores without prescription. Previous research also showed that DTC users of priscription drugs were usually influenced by mass media and friends/relatives rather than medical professionals. This phenomenon is different from common priscription drugs, but similar to many consumer products.
It is important to seek support from key opinion leaders in medical professionals when marketing DTC prescription drugs. However, the main marketing target should be consumers and the main marketing tools should be a “pull” strategy(including various kinds of media exposures) accompanied by a “push” strategy (which emphasizes positive image and efficacy of the DTC drugs).
DTC prescription drugs, such as ED drugs, may usually be high-involvement products initially. Since there is only a few differences among various brands, it then usually becomes a low-involvement habitual buying behavior. If we can make consumers to become more familiar with a certain brand, they will have stronger brand belief, and will be used to buying the same brand repeatedly.
The “pull” strategy for promoting DTC priscription can easily inspire the need and motivation of potential consumers, and then foster their positive attitude toward product through behavior learning process or product experience. However, because of its consumer product characteristics, the potential customers may become resistant to the promotion efforts, and so the expansion of market size may be limited.
It is not easy to create cost advantage for DTC prescription drugs. But the market leader may enjoy first mover advantage and differentiate itself through product attributes (such as efficacy), and promotion intensity(such as wider exposure).
Since there is a limit to drug patent, pharmaceutical firms should manage to navigate through the product life cycle, such as developing a lower-price product to maintain future market leadership, or phasing out from current market and move to other fields.


Keywords:Direct-to-Consumer (DTC), Prescription Drug, Erectile Dysfunction(ED),
Consumer Behavior, Marketing Strategy.
口試委員會審定書...............................i
誌 謝.......................................ii
中文摘要.....................................iii
英文摘要......................................iv
目 錄........................................vi
圖目錄.......................................vii
表目錄........................................ix
第一章 緒 論..................................1
第一節、研究背景...............................1
第二節、研究動機與問題.........................3
第三節、研究目的...............................5
第四節、研究流程與方法.........................6
第二章 文獻探討與理論回顧......................9
第一節、DTC處方藥之行銷相關研究................9
第二節、產業分析與競爭理論.....................9
第三節、行銷策略理論..........................18
第四節、消費者行為理論........................25
第五節、品牌經營理論..........................31
第三章 產業環境...............................36
第一節、外在環境分析..........................36
第二節、產業及個案公司分析....................38
第三節、產品環境現況..........................46
第四節、產業之五力分析........................53
第五節、產品之消費者行為分析..................54
第四章 個案產品行銷策略分析...................57
第一節、上市前與上市導入期(1997-2000).......57
第二節、上市後之成長期(2001-2002)...........59
第三節、上市後之競爭期(2003-2004)...........62
第四節、上市後之成熟期(2005~2008)...........66
第五節、勃起功能障礙處方藥之行銷策略分析......86
第五章 結論與建議.............................99
第一節、主要發現..............................99
第二節、管理意涵.............................102
第三節、研究限制.............................103
第四節、未來可能的研究方向...................103
參考文獻.....................................104
中文文獻:

1.吳東霖,治療男性勃起功能藥物在台灣市場競爭策略之探討,國立中山大學高階經營碩士班論文,民國93年。
2.許富得,國際性大藥廠如何成功上市新產品,臺灣大學高階公共管理組碩士論文,民國95年。
3.徐梅屏,媒體行銷的奇葩:醫療產業的置入性行銷初探,國立臺灣大學知識管理組碩士論文,民國93年。
4.張博勝,自費型醫藥產品行銷策略與消費者行為研究,國立政治大學經營管理碩士學程碩士論文,民國95年。
5.黃俊英,行銷研究概論,第二版,台北:華泰書局,民國86年。
6.焦經隆,女性消費者產品涉入對知覺風險、資訊搜尋及散佈之影響-以健康食品為例,國立成功大學管理學院高階管理碩士在職專班碩士論文,民國92年。
7.葉權儀,消費者行為與行銷策略研究,台北:六國出版社,民國83年。
8.謝文雀譯,行銷管理- 亞洲觀點,第三版,台北:華泰書局出版,民國93年。
9.謝凱宇,林舒柔譯,現代策略管理,台北:科大文化出版,民國93年

英文文獻:
1.Aaker, DA. Strategic Market Management. 3th ed., New York: John Wiley and Sons. p.12. 1995.
2.Althof SE. When an erection alone is not enough:biopsychosocial obstacles to lovemarking. Int J Impot Res2002;14 Suppl 1: S99-S104.
3.Anderson EW, Sullive MW.: The antecedents and consequence of customer satisfaction for firms. Marketing Science. 12:125-143,1993.
4.Araujo AB, Johannes CB, Feldman HA, Derby CA, McKinlay JB.: Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Male Aging Study, American Journal of Epidemiology. 152:533-541, 2000.
5.Ansong KS, Lewis C, Jenkins P, Bell J. Epidemiology of erectile dysfunction: a community-based study in rural New York State. Ann Epidemiol; 10:293-6, 2000.
6.Assael H. Consumer Behavior and Marketing Action. 6th ed., Ohio USA: South-Western College Publishing, 2001.
7.Biel AL. How Brand Image Drives Brand Equity? Journal of Advertising Research, 32(6) : 6-12, 1992.
8.Bogdan R. & Biklen, S., Qualitative Research for Education: An Introduction to Theory and Methods. Boston, Ma: Allyn and Bacon, 1982.
9.Braun M et al. Epidemiology of erectile dysfunction: results of the ''Cologne Male Survey''. Int J Impot Res. 12:305-11, 2000.
10.Brock G., Nehra A, lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H.: Safety and efficacy of vardenafil for the treatment of men with erectile dysfuncyion after radical retropubic prostatectomy. Journal of Urology. 170(4 Pt 1):1278-1283, 2003.
11.Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkines V, Anglin G, Whitaker S.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Journal of Urology. 168(4 Pt 1): 1322-1336, 2002.
12.Chew KK et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res. 12:41-5, 2000.
13.Chen KK., Chiang HS., Jiann BP. et al. Prevalence of erectile dysfunction and impacts on sexual activity and self-reported intercourse satisfaction in men older than 40 years in Taiwan. Int J Impot Res, 16: 249, 2004.
14.Churchill GA, Jr., Surprenant C.: An investigation into the determinants of customer satisfaction. Journal of Marketing Research. 19:491-504, 1982.
15.Cunningham DJ, Iyer R. Does DTC mean“Direct to court”? , Journal of consumer Marketing.22 (7) 412-422,2005.
16.Diokno AC, Brown MB, Herzog AR. Sexual function in the elderly. Arch Intern Med. 150:197-200, 1990.
17.Dobni D. and Zinkhan GM. In Search of Brand Image: A Foundation Analysis. Advances in Consumer Research. 17, p.110-119, 1990.
18.Drucker PF., Management: Tasks, Responsibilities, Practices, New York: Harper & Row, 1973.
19.Engel JF., Blackwell, RD. & Miniard, PW. Consumer Behavior. 8th ed., Hinsdale, Ill. : Dryden Press, 2001.
20.Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol; 151:54-61, 1994.
21.Fink HA, MacDonald R, Rutks IR, Nelson DB, Wilt TJ. Sildenafil for male erectile dysfunction : a systematic review and meta-analysis. Archives of Internal Medicine. 162(12):1349-1360, 2002.
22.Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steer WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine338:1397-1404, 1998.
23.Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 26:777-783, 2003.
24.Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP. Clinical efficacy of sildenafil citrate and predictors of long-term response, Journal of Urology 170(2 Pt 1):503-506, 2003.
25.Gwinner KP, Gremler DD, Bitner MJ. Relational benefits in service industries: The customers perspective. Journal of the Academy of Marketing Science 26:101-114, 1998.
26.Grimm PE. Ab Components’ impact on brand preference. Journal of business research 58: 508-517, 2005.
27.Gresser U Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature. European Journal of Medical Reserch. 7:435-446,2002.
28.Gronroos C. An Applied Service Marketing Theory, European Journal of Marketing, 16 (7), p.30-41, 1982.
29.Gronroos C. A Service Quality Model and its Marketing Implication, European Journal of Marketing, 18(4), p.36-44, 1984.
30.Gronroos C. Service Management and Marketing: A Customer Relationship Management Approach, New York: John Wiley & Sons, 1990.
31.Hellstrom WJ, Gittelman M, karlin G., Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men eith erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. Journal of Andrology.23:763-771, 2002.
32.Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T,
Padma-Nathan H: vardenafil Sdudy Group. Sustained efficacy and tolerability of
vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men
with erectile dysfunction: result of a randomized , double-blind , 26-week
placebo-controlled pivotal trial. Urology. 61(4 Suppll): 8-14,2003.
33.Hill CW. and Jones GR. Strategic Management Theory, 5th ed., Boston, MA: Houghton Mifflin, 2001.
34.Hill P, Wang R. Overview of contemporary penile rehabilitation therapies. Adv Urol. 481218, 2008.
35.Howard J. Consumer Behavior in Marketing Strategy, Englewood Cliffs, N.J. Prentice Hall, 1989.
36.Huh J Langteau R. Presumed Influence of direct to consumer (DTC) prescription
Drug Advertising on Patients. Journal of Advertising. 36(3): 151-172, 2007.
37.IMS Taiwan 2003, 2004, 2005, 2006, 2007.
38.Kevin R, Berkowitz E, Hartley S, Rudelius W. Marketing, 7th. Boston:
McGraw-Hill. Irwin, pp274-277, 2003.
39.Kotler, P., Ang, S. H., Leong, S. M., and Tan, C. T. Marketing Management- An
Asian Perspective, New York: Prentice Hall, 1999.
40.Kotler P. Marketing Management: Analysis, Planning, Implementation and
Control, 6th ed., Englewood Cliffs. NJ: Prentice Hall, 1988.
41.Kotler P. Marketing Management. Upper Saddle River, N.J. Prentice Hall, 2000.
42.Maggard JP. Positioning Revisited. Journal of marketing, 40(1), p.63-66, 1976.
43.MaMahon CG, Samali R, Johnson H.: Efficacy. Safety and patient acceptance of
sildenafil citrate as treatment for erectile dysfunction. Journal of Urology,
164:1192-1196, 2000.
44.Mayer M, Beatty SE, Coleman JE, Reynolds KE, Lee J. Customer-sales associate
retail relationships. Journal of Retailing, 72:223-247, 1996.
45.McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 12:S6-S11, 2000.
46.Miles, RE. and Snow, CC. ,Organizational Strategy, Structure, and Process, New York: McGraw-Hill, 1978.
47.Nagle, T., The Strategy and Tactics of Pricing. 3rd ed. Englewood Cliffs, NJ: Prentice Hall, 2002.
48.National Health Administration. Executive Yuan RoC. Health Statistics: I. Vital Statistics, 1999. Taipei, Taiwan,: National Health Administration, 2000.
49.National Health Administration. Executive Yuan RoC. National survey on nutrition, dietary style, and risk factors of cardiovascular disease, 1990-1996. Taipei, Taiwan,: National Health Administration., 1998.
50.Nicosia FM., Consumer Decision Process: Marketing and Advertising Implication, Englewood Cliffs, N.J.: Prentice-Hall, 1968.
51.Nicolosi A., Glasser DB., Kim SC. et al.: Sexual behavior and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int. 95: 609-612, 2005.
52.NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 270:83-90, 1993.
53.NIH Consensus Development Panel on Impotence. NIH consensus conference: impotence. Journal of Amarican Medical Association. 270:830, 1993.
54.Porter M. Competitive Strategy: Techniques for Analyzing Industries and Competitors, New York: The Free Press, 1980.
55.Porter M. Competitive Advantage of Nations, New York: Free Press, 1990.
56.Pride W. M. & Ferrell, O.C. Marketing: Concepts and Strategies, 12th ed., Boston, MA: Houghton Mifflin Company, 2003.
57.Rafiq & Ahmed, Advances in the Internal Marketing Concept: Definitions, Synthesis and Extension. Journal of Services Marketing, 14(6) p. 449-462, 2000.
58.Reynolds KE, Beatty SE. Customer benefits and company consequence of customer-salesperson relationships in retailing. Journal of Retailing,75:11-32, 1999.
59.Rogers EM. Diffusion of Innovations, 4th ed., New York: Free Press, 1950.
60.Rosen RC., Cappelleri JC., Smith M. D. et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile function (IIEF-5) as a diagnostic tool for ED. Int. J Imp Res, 11: 319-322, 1999.
61.Saenz de Tejada I., Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care25:2159-2164, 2002.
62.Schartizer D, Kollarits HC. Satisfied customers: profitable customer relationships: pharmaceutical marketing: How pharmaceutical representatives can achive economic success through relationship management with general-practitioners-an empirical study. Today Quality Management,11:955-965, 2000.
63.Schiffman LG. & Kanuk LL. Consumer Behavior, 9th ed., New Jersey: Prentice-Hall, 2007.
64.Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151-7.
65.Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc. 45:63-72, 2005.
66.Stief CG, Uckert S, becker AJ, Truss MC, Jonas U. The effect of the specific phosphodiesterase inhibitors on human and rabbit carvernous tissue in vitro and in vivo. Journal of Urology 159:1390-1393, 1998.
67.Thompson IM, Tangen CM, goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 294:2996-3002, 2005.
68.Tikkanen MJ, Jackson G, Tammela T, et al. Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention. Int J Clin Pract. 61:265-8, 2007.
69.Wendell RS. Product Differentiation and Market Segmentation as Alternative Marketing Strategies, Journal of Marketing, 21(1), p. 3-8. ,1956.
70.Wind Y. Issues and Advances in Segmentation Research, Journal of Marketing Research, 15(3), p.317-337, 1978.
71.Wu CJ, Hsieh JT, Lin JS, et al. Comparison of prevalence between self-reported erectile dysfunction and erectile dysfunction as defined by five-item International Index of Erectile Function in Taiwanese men older than 40 years. Urology. 69:743-7, 2007.
72.Yin RK. Case Study Research Design & Methods. 2nd ed., Beverly Hills, Calif: Sage Publications, 1994.

參考網站:
1.台灣勃起功能障礙諮詢暨訓練委員會網站,www.edact.org.tw。
2.威而鋼 (Viagra) 英文網站,www.viagra.com。
3.犀利士 (Cialis) 英文網站,www.cialis.com。
4.樂威壯 (Levitra) 英文網站,www.levitra.com。
5.www.in99.com.tw。
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊